Stockreport

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China [Yahoo! Finance]

CASI Pharmaceuticals, Inc. - Ordinary Shares  (CASI) 
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations
PDF development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech [Read more]